Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Price Target at $4.60

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $4.60.

Separately, Weiss Ratings lowered shares of ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd.

ALX Oncology Stock Performance

ALXO opened at $1.94 on Wednesday. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07. The firm has a market cap of $268.26 million, a PE ratio of -1.72 and a beta of 0.39. The business has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $1.94. ALX Oncology has a fifty-two week low of $1.01 and a fifty-two week high of $2.66.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, equities analysts predict that ALX Oncology will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On ALX Oncology

Several hedge funds have recently made changes to their positions in the company. Beacon Pointe Advisors LLC acquired a new position in ALX Oncology in the 2nd quarter worth approximately $26,000. Callan Family Office LLC purchased a new stake in shares of ALX Oncology in the second quarter valued at $46,000. Invesco Ltd. purchased a new stake in shares of ALX Oncology in the first quarter valued at $46,000. The Manufacturers Life Insurance Company acquired a new stake in shares of ALX Oncology in the second quarter worth $64,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of ALX Oncology during the third quarter valued at $66,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.